Pharma Mar, S.A. (FRA:PMRA)

Market Cap	1.36B -1.6%
Revenue (ttm)	179.28M +7.3%
Net Income	34.01M +5,367.0%
EPS	1.95
Shares Out	n/a
PE Ratio	39.96
Forward PE	24.76
Dividend	0.80 (0.98%)
Ex-Dividend Date	Jun 25, 2025

Volume	n/a
Average Volume	6
Open	78.30
Previous Close	79.25
Day's Range	78.30 - 78.30
52-Week Range	70.60 - 101.20
Beta	n/a
RSI	48.06
Earnings Date	Feb 28, 2026

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, China, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata for the treatment of soft tissue sarcoma and recurrent ovarian cancer; Aplidin ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1986
• Employees: 500
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PMRA

Financial Performance

In 2024, Pharma Mar's revenue was 174.86 million, an increase of 10.56% compared to the previous year's 158.15 million. Earnings were 26.13 million, an increase of 2197.71%.